First-in-Class TYK Inhibitor Shows Durable Effect for Psoriasis First-in-Class TYK Inhibitor Shows Durable Effect for Psoriasis
The 52-week data from two pivotal trials with deucravacitinib, a first-in-class inhibitor of tyrosine kinase 2 (TYK2), demonstrated durable control of moderate-to-severe plaque psoriasis.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news